EANS-News: Epigenomics AG Licenses Biomarker for Development of Prostate Cancer Test to Predictive Biosciences

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

cooperations/molecular diagnostics

Berlin, Germany and Seattle, WA, U.S.A., (euro adhoc) - April 28,
2009 - Epigenomics AG (Frankfurt, Prime Standard: ECX), a cancer
molecular diagnostics company, today announced that it has entered
into a non-exclusive licensing agreement for its proprietary
biomarker mGSTP1 with U.S.-based Predictive Biosciences Incorporated,
an innovative and privately held cancer molecular diagnostics
company.

Under the agreement, Predictive Biosciences has obtained rights to
uses of the GSTP1 DNA methylation biomarker (mGSTP1) to establish and
commercialize a molecular-based laboratory-developed test that can
help urologists and pathologists better diagnose and manage prostate
cancer. Financial terms were not disclosed.

Prostate cancer is the leading cause of cancer death in men in the
U.S., with more than 230,000 cases diagnosed annually and more than 1
million prostate biopsies performed each year. Epigenomics and others
have demonstrated that methylated DNA of the GSTP1 gene in tissue may
indicate the presence of prostate cancer. A test that detects the DNA
methylation of the gene GSTP1 in combination with conventional
histopathology may augment the accuracy of prostate cancer diagnosis
- in particular, in cases with suspicious but inconclusive histology
findings or patients with elevated PSA but repeatedly negative
biopsies.

"We are pleased that Predictive Biosciences is adding DNA methylation
to its menu of molecular diagnostic tests using our technology and
biomarker. They share our goal to develop cancer tests that will help
physicians achieve improved health outcomes for their patients
through better diagnosis of prostate cancer", said Geert Nygaard, CEO
of Epigenomics.

About Epigenomics

Epigenomics is a molecular diagnostics company with a focus on the
development of novel products for cancer. Using DNA methylation
biomarkers, Epigenomics' tests in development aim at diagnosing
cancer at an early stage before symptoms occur and thereby may reduce
mortality from this dreaded disease.

Epigenomics' product pipeline contains a validated biomarker for the
early detection of colorectal cancer in blood plasma, and further
proprietary DNA methylation biomarkers at various stages of
development for prostate and lung cancer detection in urine, blood
and bronchial lavage specimens. Epigenomics' biomarker mSEPT9 for the
early detection of colorectal cancer in a simple blood sample
demonstrated continuously highest performance in multiple clinical
studies with in total about 3,500 individuals tested. A large
prospective clinical study - PRESEPT - for evaluation of mSEPT9 in a
screening population is currently under way (www.presept.net).

For development and global commercialization of in vitro diagnostic
test products, Epigenomics pursues a non-exclusive partnering
strategy. Strategic diagnostics industry partners include Abbott
Molecular, Philips, Sysmex Corporation and Quest Diagnostics
Incorporated for diagnostics test products and services, and QIAGEN
N.V. for sample preparation solutions and research products.

Partners in the health care industry and the biomedical research
community can access Epigenomics' portfolio of proprietary DNA
methylation technologies and biomarkers protected by more than 150
patent families through research products, Biomarker Services, IVD
Development Collaborations, and Licensing. The company is
headquartered in Berlin, Germany, and has a wholly owned subsidiary
in Seattle, WA, U.S.A. For more information, please visit
Epigenomics' website at www.epigenomics.com.

Epigenomics legal disclaimer. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Epigenomics AG

Dr. Achim Plum

Sen. VP Corporate Development

Tel: +49 30 24345 368

achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse München / free trade